INFLAMMATORY BOWEL DISEASE (IBD) · White paper
Inflammatory Bowel Disease (IBD) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About inflammatory bowel disease (ibd) — and why its trials are hard
Inflammatory bowel disease, comprising Crohn's disease and ulcerative colitis (UC), is a chronic relapsing inflammatory disorder of the gastrointestinal tract. Drug development is uniquely challenging because the landscape is saturated with Phase 2/3 programs competing for the same moderate-to-severe patients: moderate-to-severe IBD trials rose from roughly 7 in 1998 to about 147 in 2018, and around 50% of trials miss recruitment timelines. The market is dominated by established biologics such as adalimumab. Modern therapy spans anti-TNF agents (infliximab, adalimumab, golimumab, certolizumab), anti-integrins (vedolizumab, natalizumab), anti-IL-12/23 (ustekinumab), JAK inhibitors (tofacitinib, upadacitinib), and S1P modulators (ozanimod). Pivotal trials rely on clinical remission, clinical response, endoscopic response, and mucosal healing. Failures illustrate recurring themes: poor patient selection (heavy concomitant corticosteroid use), mistimed efficacy data collection, over-extrapolation from proof-of-concept data, and non-clinical hurdles such as manufacturing deficiencies. These lessons emphasize disciplined endpoint choice, appropriate populations, and adaptive designs that conserve a scarce participant pool.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Infliximab (Remicade) | 1998 (Crohn's), 2005 (UC) | Moderate-to-severe Crohn's disease and ulcerative colitis | ACCENT / ACT 1 & 2 | Clinical remission, mucosal response | Established anti-TNF benefit in induction and maintenance of remission |
| Adalimumab (Humira) | 2007 (Crohn's), 2012 (UC) | Moderate-to-severe Crohn's disease and ulcerative colitis | CLASSIC / ULTRA | Clinical remission | Anti-TNF mAb; became the highest-revenue biologic (>USD 20 billion) |
| Vedolizumab (Entyvio) | 2014 | Moderate-to-severe Crohn's disease and ulcerative colitis | GEMINI 1 & 2 | Clinical response, clinical remission, mucosal response | Gut-selective anti-alpha4beta7 integrin efficacy vs placebo |
| Ustekinumab (Stelara) | 2016 (Crohn's), 2019 (UC) | Moderate-to-severe Crohn's disease and ulcerative colitis | UNITI / UNIFI | Clinical remission, endoscopic response | Anti-IL-12/23 induction and maintenance benefit vs placebo |
| Tofacitinib (Xeljanz) | 2018 | Moderate-to-severe ulcerative colitis | OCTAVE Induction & Sustain | Clinical remission, mucosal response | Oral JAK inhibitor achieved remission vs placebo in UC |
| Upadacitinib (Rinvoq) | 2022 (UC), 2023 (Crohn's) | Moderate-to-severe ulcerative colitis and Crohn's disease | U-ACHIEVE / U-EXCEL | Clinical remission, endoscopic response | Oral selective JAK1 inhibitor benefit vs placebo |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in inflammatory bowel disease (ibd) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Tofacitinib (in Crohn's disease) — Phase 2 Crohn's program (Pfizer) | Failed to demonstrate a statistically significant treatment effect in Crohn's disease Phase 2 (despite later UC success) | High proportion of patients on concomitant corticosteroids and endpoint/population selection issues |
| Etrolizumab — Phase 3 program (Roche) | Failed to consistently meet primary efficacy endpoints across a suite of Phase 3 trials | Timing and collection of early efficacy data in a large, complex development program |
| Mongersen (GED-0301) — Phase 3 interim futility analysis (Celgene/BMS) | Stopped for futility; failed to demonstrate efficacy in Phase 3 | Difficulty extrapolating promising early-phase/proof-of-concept data to later-phase success |
Choosing the right endpoint
Primary endpoints that matter in inflammatory bowel disease (ibd) trials
- Clinical remission — Primary pivotal endpoint, typically defined by a low composite disease-activity index (e.g., Mayo score in UC, CDAI in Crohn's)
- Clinical response — Defined reduction in disease-activity index from baseline; used for induction assessment
- Endoscopic response / mucosal healing — Objective endoscopic improvement; increasingly required to demonstrate durable, meaningful benefit
- Corticosteroid-free remission — Remission without ongoing steroids; reflects clinically meaningful maintenance
- Histologic remission — Emerging deeper endpoint reflecting resolution of microscopic inflammation
How iNGENū runs inflammatory bowel disease (ibd) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Inflammatory Bowel Disease (IBD) clinical trials — FAQs
Why is patient recruitment so difficult in IBD trials?
What endpoints does the FDA expect for IBD approvals?
Do trial failures always mean the drug does not work?
Ready to discuss your inflammatory bowel disease (ibd) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal